Lipenan (Atorvastatin, Ezetimibe)

Atorvastatin blocks HMG‑CoA reductase, the enzyme responsible for hepatic cholesterol synthesis, while ezetimibe inhibits the NPC1L1 transporter in the intestinal wall, reducing dietary and biliary cholesterol absorption. The dual action provides additive reductions in LDL‑C and total cholesterol.

The dose of Lipenan is set by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, and tolerance. Dosage adjustments are made according to therapeutic response and safety monitoring, and patients should follow the prescriber’s specific instructions.

Lipenan is generally not recommended during pregnancy or lactation unless the potential benefit justifies the risk. Statins are contraindicated in pregnancy, and ezetimibe lacks sufficient safety data; clinicians should consider alternative therapies and discuss risks with the patient.

To order Lipenan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and the necessary import documentation.

Compared with statin monotherapy, Lipenan adds ezetimibe to achieve greater LDL‑C reduction, especially in patients needing additional lowering or who cannot tolerate high‑dose statins. It offers a convenient fixed‑dose oral option, potentially improving adherence versus taking separate agents.

Lipenan tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Lipenan is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed, to maintain the intended release profile.

The most serious adverse reactions include rhabdomyolysis, severe liver injury, and hypersensitivity reactions such as angioedema. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or signs of an allergic reaction to their healthcare provider.

Lipenan is contraindicated in patients with active liver disease, unexplained persistent elevations of transaminases, known hypersensitivity to atorvastatin, ezetimibe, or any excipients, and in women who are pregnant or may become pregnant unless the benefit outweighs the risk. Caution is also advised for those on certain interacting medications.